Compounds > 5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl)isoxazole
Page last updated: 2024-12-09

5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl)isoxazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl)isoxazole: inhibits Hsp27 phosphorylation; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID927908
CHEMBL ID1552019
SCHEMBL ID1167690
MeSH IDM0494673

Synonyms (19)

Synonym
OPREA1_366087
NCGC00165819-01
(6z)-4-ethyl-3-methoxy-6-[4-(4-methoxyphenyl)-2h-1,2-oxazol-5-ylidene]cyclohexa-2,4-dien-1-one
4-ethyl-3-methoxy-6-[4-(4-methoxyphenyl)-2h-isoxazol-5-ylidene]cyclohexa-2,4-dien-1-one
129414-88-6
A805937
CHEMBL1552019
kribb3
5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl)isoxazole
SCHEMBL1167690
153151-22-5
4-ethyl-3-methoxy-6-[4-(4-methoxyphenyl)-1,2-oxazol-5(2h)-ylidene]cyclohexa-2,4-dien-1-one
DTXSID00425315
J-005675
4-ethyl-5-methoxy-2-(4-(4-methoxyphenyl)isoxazol-5-yl)phenol
copper(ii)-2,3,9,10,16,17,23,24-octa-n-hexyl-29h,31h-phthalocyanine
4-ethyl-5-methoxy-2-[4-(4-methoxyphenyl)-1,2-oxazol-5-yl]phenol
4-ethyl-5-methoxy-2-[4-(4-methoxyphenyl)-5-isoxazolyl]phenol
CS-0068882
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency14.12540.00798.23321,122.0200AID2546; AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID672086Inhibition of Hsp27 phosphorylation in human SKBR3 cells at 0.5 to 1 uM after 24 hrs by immunofluorescence analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Identification of a class of novel tubulin inhibitors.
AID1497701Antitumor activity against human HCT116 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 50 mg/kg, ip for 16 days2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
The recent progress of isoxazole in medicinal chemistry.
AID672088Binding affinity to pure Hsp27 in human SKBR3 cell lysate at 0.5 to 1 uM after 1 hr by Western blot analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Identification of a class of novel tubulin inhibitors.
AID568649Inhibition of tubulin polymerization for 70 mins by microtubule polymerization assay2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Biological evaluation of KRIBB3 analogs as a microtubule polymerization inhibitor.
AID1497702Antitumor activity against human HCT116 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 100 mg/kg, ip for 16 days2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
The recent progress of isoxazole in medicinal chemistry.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's9 (75.00)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.64 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bromide
Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)		2.0210halide anion;
monoatomic bromine
nocodazole
[no description available]		2.0710aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		3.8100isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
bay 11-7082
(E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.		2.2110nitrile;
sulfone		apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor
jcc 76
[no description available]		2.0710
nsc751382
[no description available]		2.0710
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		03.3920
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.3920
Colitis, Mucous
[description not available]		02.2510
Innate Inflammatory Response
[description not available]		02.2510
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		02.2510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.2510
Irritable Bowel Syndrome
A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.		02.2510
Cancer of Prostate
[description not available]		02.2110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.2110
Liver Steatosis
[description not available]		02.1310
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		02.1310
Leucocythaemia
[description not available]		02.0710
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.0710
Invasiveness, Neoplasm
[description not available]		02.0210